Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Transition from Selexipag to Treprostinil in PAH
NCT03016468Phase 2Withdrawn
- Sponsor
- United Therapeutics Corporation
- Start
- May 2017
- Primary completion
- Sep 2018
- Modality
- Orthosteric Ligands
01
Overview
A Phase 2 trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Planned start May 2017; status: withdrawn.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03016468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03016468.